Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Active not recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Liposarcoma 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Oxaliplatin 4Paclitaxel 3Capecitabine 3pembrolizumab 2fludarabine 2Trastuzumab 2S 1 (combination) 2Ramucirumab 2Polymerase Chain Reaction 2Irinotecan 2Gastric Bypass 2Fluorouracil 2Cyclophosphamide 2Biopsy 2zimberelimab 1tusamitamab ravtansine 1talazoparib 1relatlimab 1olaparib 1milademetan 1atezolizumab 1apatinib 1XELOX 1Valganciclovir 1Taxes 1Saline Solution 1Nivolumab 1Methods 1Lubricant Eye Drops 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Stomach Neoplasms × olaparib × Clear all
NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Ellipses Pharma

Phase 2 Withdrawn
GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡